Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study
- PMID: 32376304
- DOI: 10.1016/j.hrthm.2020.04.036
Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study
Abstract
Background: Patients with chronic renal disease on hemodialysis (HD) have limited vascular access and are at high risk of bacteremia. The subcutaneous implantable cardioverter-defibrillator (S-ICD) avoids vascular access, so it may be advantageous in this patient population.
Objective: The purpose of this study was to report outcomes of patients with end-stage renal disease enrolled in the multicenter S-ICD post-approval study (PAS).
Methods: S-ICD PAS patients were stratified on the basis of the presence (group 1) or absence (group 2) of HD at the time of implantation. Baseline demographic and clinical characteristics were collected. Perioperative and intermediate-term outcomes 365 days postimplantation were compared between the 2 groups.
Results: There were 220 patients on HD (13.4%) at the time of implantation out of 1637 patients enrolled in the S-ICD PAS. Patients on HD (group 1) were older (57.4 ± 13.2 years vs 52.5 ± 15.2 years; P < .0001), more likely to be of African descent (48.6% vs 25.1%; P < .0001), and had lower ejection fraction (28.6% ± 11.3% vs 32.6% ± 14.9%; P < .0001) as compared with patients not on HD (group 2). Group 1 had more comorbidities and mortality was higher (17.4% vs 3.7%) than did group 2. The rate of complications calculated using the Kaplan-Meier estimate did not differ between the 2 groups (overall P = .9169), with a 1-year rate of 7.9% and 7.7% for groups 1 and 2, respectively. The rate of appropriate shocks was significantly higher in group 1 (Kaplan-Meier analysis, P = .0003), as was inappropriate shocks (P = .0137).
Conclusion: S-ICD is associated with similar adverse event rates but a higher risk of inappropriate and appropriate therapy in dialysis patients than in nondialysis patients.
Trial registration: ClinicalTrials.gov NCT01736618.
Keywords: Arrhythmia; Dialysis; End-stage renal disease; Implantable cardioverter-defibrillator; Subcutaneous ICD; Sudden cardiac death; Ventricular arrhythmia.
Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Outcome of Subcutaneous Implantable Cardioverter Defibrillator Implantation in Patients with End-Stage Renal Disease on Dialysis.J Cardiovasc Electrophysiol. 2015 Aug;26(8):900-904. doi: 10.1111/jce.12705. Epub 2015 Jun 16. J Cardiovasc Electrophysiol. 2015. PMID: 25952566
-
Dialytic interval and the timing of electrocardiographic screening for subcutaneous cardioverter-defibrillator placement in chronic hemodialysis patients.J Interv Card Electrophysiol. 2018 Jul;52(2):179-184. doi: 10.1007/s10840-018-0343-1. Epub 2018 Mar 10. J Interv Card Electrophysiol. 2018. PMID: 29525912
-
Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis.J Interv Card Electrophysiol. 2016 Mar;45(2):219-23. doi: 10.1007/s10840-015-0093-2. Epub 2016 Jan 14. J Interv Card Electrophysiol. 2016. PMID: 26768264
-
Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol. 2018 Oct 2;72(14):1653-1676. doi: 10.1016/j.jacc.2017.10.052. Epub 2017 Oct 30. J Am Coll Cardiol. 2018. PMID: 29097297
-
Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis.Heart Rhythm. 2021 Mar;18(3):382-391. doi: 10.1016/j.hrthm.2020.11.013. Epub 2020 Nov 16. Heart Rhythm. 2021. PMID: 33212250
Cited by
-
Cardiac Device Therapy in Patients with Chronic Kidney Disease: An Update.J Clin Med. 2024 Jan 17;13(2):516. doi: 10.3390/jcm13020516. J Clin Med. 2024. PMID: 38256650 Free PMC article. Review.
-
Subcutaneous cardioverter defibrillator implanted intermuscularly in patients with end-stage renal disease requiring hemodialysis: 5-year follow-up.J Interv Card Electrophysiol. 2025 Jun;68(4):749-756. doi: 10.1007/s10840-024-01767-1. Epub 2024 Feb 22. J Interv Card Electrophysiol. 2025. PMID: 38383674
-
Do Implantable Cardioverter-Defibrillators Prevent Sudden Cardiac Death in End-Stage Renal Disease Patients on Dialysis?J Clin Med. 2024 Feb 19;13(4):1176. doi: 10.3390/jcm13041176. J Clin Med. 2024. PMID: 38398488 Free PMC article. Review.
-
ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing.J Am Coll Cardiol. 2025 Mar 25;85(11):1213-1285. doi: 10.1016/j.jacc.2024.11.023. Epub 2025 Jan 13. J Am Coll Cardiol. 2025. PMID: 39808105
-
Comparison of infection and complication rates associated with transvenous vs. subcutaneous defibrillators in patients with stage 4 chronic kidney disease: a multicenter long-term retrospective follow-up.Front Cardiovasc Med. 2024 Apr 10;11:1397138. doi: 10.3389/fcvm.2024.1397138. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38660482 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical